Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Paclitaxel and NALIRIFOX in Pancreatic Cancer with Peritoneal Carcinomatosis
NCT07030283Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Colorado Denver. Primary endpoint: Adverse event rate at 7 months. Started Dec 2025; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07030283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030283.